{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:28:28Z","timestamp":1790692108090,"version":"4.1.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.2215\/cjn.12111019","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T19:15:23Z","timestamp":1573067723000},"page":"1682-1683","source":"Crossref","is-referenced-by-count":5,"title":["Monitoring Complement Activation"],"prefix":"10.2215","volume":"14","author":[{"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris, Laboratory of Immunology, H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies.","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome.","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome.","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome.","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome.","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3109\/14767058.2012.694923","article-title":"The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.","volume":"25","author":"Crovetto","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort.","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: Outcome with ongoing eculizumab.","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation.","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12111019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:20Z","timestamp":1786369160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.12111019"}},"subtitle":["The New Conundrum in Thrombotic Microangiopathies"],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.12111019","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]}}}